Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Achieve Life Sciences (ACHV) Assets (2016 - 2026)

Achieve Life Sciences (ACHV) has disclosed Assets for 17 consecutive years, with $33.1 million as the latest value for Q1 2026.

  • Quarterly Assets rose 21.01% to $33.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $33.1 million through Mar 2026, up 21.01% year-over-year, with the annual reading at $41.8 million for FY2025, 8.17% up from the prior year.
  • Assets for Q1 2026 was $33.1 million at Achieve Life Sciences, down from $41.8 million in the prior quarter.
  • The five-year high for Assets was $70.0 million in Q1 2024, with the low at $19.4 million in Q4 2023.
  • Average Assets over 5 years is $38.6 million, with a median of $34.0 million recorded in 2022.
  • The sharpest move saw Assets skyrocketed 236.71% in 2024, then crashed 60.93% in 2025.
  • Achieve Life Sciences' Assets stood at $30.0 million in 2022, then crashed by 35.37% to $19.4 million in 2023, then soared by 99.44% to $38.6 million in 2024, then increased by 8.17% to $41.8 million in 2025, then fell by 20.78% to $33.1 million in 2026.
  • Per Business Quant, the three most recent readings for ACHV's Assets are $33.1 million (Q1 2026), $41.8 million (Q4 2025), and $52.0 million (Q3 2025).